RNS Number : 7218H Renalytix PLC 08 April 2022 Renalytix plc ("Renalytix" or the "Company") Issue of shares NEW YORK and SALT LAKE CITY , 8 April, 2022 - Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 22,814 new
RNS Number : 7737H Renalytix PLC 08 April 2022 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , JAPAN , THE REPUBLIC OF SOUTH AFRICA , NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW.
LONDON and SALT LAKE CITY, March 31, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today
RNS Number : 7325G Renalytix PLC 31 March 2022 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , JAPAN , THE REPUBLIC OF SOUTH AFRICA , NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR
RNS Number : 6807G Renalytix PLC 31 March 2022 Renalytix plc ("Renalytix" or the "Company") Half Year Report LONDON and SALT LAKE CITY , March 31, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE : RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing
NEW YORK and SALT LAKE CITY, March 30, 2022 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced that, following the Company’s announcement on February 22, 2022, Timothy Scannell has been appointed to the Board as an independent Non-Executive Director of Renalytix. As an
RNS Number : 5577G Renalytix PLC 30 March 2022 Renalytix plc ("Renalytix" or the "Company") Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors NEW YORK and SALT LAKE CITY , March 30, 2022 - Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) announces that, following the
KidneyIntelX RAPID biobank program and partners on track to reach over 30,000 biospecimens with matched electronic health records from multiple centers across the U.S. NEW YORK and SALT LAKE CITY, March 29, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the
RNS Number : 3159G Renalytix PLC 29 March 2022 Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes KidneyIntelX RAPID biobank program and partners on track to reach over 30,000 biospecimens with matched
